|
US2021106619A1
|
|
NK-92 Bone and Brain targeting
|
|
WO2021026155A1
|
|
Artificial target cells for in-vitro car cytotoxicity and adcc validation
|
|
WO2021021705A1
|
|
Antibody pre-loaded cd16+nk-92 cells as an effective therapeutic product for tumor lysis
|
|
WO2021011488A1
|
|
Compositions comprising aldoxorubicin hydrochloride and ifosfamide and their use for the treatment of soft tissue sarcoma
|
|
WO2020112669A1
|
|
Il-2 dependent nk-92 cells with stable fc receptor expression
|
|
US2020096511A1
|
|
Sample destruction validation system and methods
|
|
WO2020028654A1
|
|
Combined invasion and cytotoxicity assay using chemokine secreting target cells
|
|
CA3106324A1
|
|
A quadricistronic system comprising a homing receptor or a cytokine, and chimeric antigen receptor for genetic modification of immunotherapies
|
|
AU2019371340A1
|
|
Elimination of CD19-positive lymphoid malignancies by CD19-CAR expressing NK cells
|
|
CA3094111A1
|
|
Elimination of pd-l1-positive malignancies by pd-l1 chimeric antigen receptor-expressing nk cells
|
|
WO2021021213A1
|
|
Anti-b7-h4 chimeric antigen receptor-modified nk-92 cells
|
|
WO2020014245A1
|
|
Cryopreservation
|
|
US2021008107A1
|
|
CIML NK cells and Methods Therefor
|
|
WO2021006875A1
|
|
Mononuclear cell derived nk cells
|
|
WO2021006876A1
|
|
Ciml nk cells and methods therefor
|
|
US2021009953A1
|
|
Mononuclear Cell Derived NK Cells
|
|
AU2019300782A1
|
|
Generating CIK NKT cells from cord blood
|
|
EP3797149A1
|
|
Methods and systems for cell bed formation during bioprocessing
|
|
KR20210011978A
|
|
Optimization of NK-92 cell growth using poloxamer
|
|
KR20210003292A
|
|
FC-EPSILON CAR
|
